{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:18:30Z","timestamp":1788452310827,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgo.2026.103068","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:35:32Z","timestamp":1784046932000},"page":"103068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study"],"prefix":"10.1016","volume":"17","author":[{"given":"Aglaia","family":"Schiza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Digkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Fjermeros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Karihtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Munoz-Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spathas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meri","family":"Utriainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Visani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukhrizah","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jgo.2026.103068_bb0005","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jgo.2026.103068_bb0010","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2026.103068_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.103068_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2026.103068_bb0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.103068_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2340\/1651-226X.2023.40365","article-title":"Clinical trials in older patients with cancer - typical challenges, possible solutions, and a paradigm of study design in breast cancer","volume":"63","author":"Karihtala","year":"2024","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2026.103068_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","volume":"5","author":"Fountzilas","year":"2020","journal-title":"ESMO Open"},{"issue":"36","key":"10.1016\/j.jgo.2026.103068_bb0040","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.18.02217","article-title":"Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4\/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis","volume":"37","author":"Howie","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.103068_bb0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clbc.2022.05.002","article-title":"Real-world treatment patterns and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer: flatiron database analysis","volume":"22","author":"Patt","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jgo.2026.103068_bb0050","article-title":"PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation","author":"M","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.103068_bb0055","article-title":"Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+\/HER2\u2212 advanced breast cancer","author":"Fatima","year":"2023","journal-title":"Cancer Res"},{"issue":"37","key":"10.1016\/j.jgo.2026.103068_bb0060","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1080\/14796694.2024.2413841","article-title":"Implementing geriatric assessment for dose optimization of CDK4\/6 inhibitors in older breast cancer patients","volume":"20","author":"Valachis","year":"2024","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2026.103068_bb0065","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s12094-024-03399-3","article-title":"Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4\/6 inhibitors in a multicentre cohort","volume":"26","author":"Pla","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2026.103068_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101585","article-title":"The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: a systematic review","volume":"14","author":"Disalvo","year":"2023","journal-title":"J Geriatr Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:38:15Z","timestamp":1788449895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1879406826002225"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.103068","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.103068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103068"}}